Sientra, Inc. (NASDAQ: SIEN), a company that offers leading
transformative treatments and technologies focused on progressing
the art of plastic surgery, today announced a strategic partnership
with Butterfly Network, Inc. (NYSE: BFLY), a leader in
point-of-care ultrasound (“POCUS”). This partnership strengthens
Sientra’s strong safety profile, backed by the industry’s leading
Platinum20™ warranty program, by empowering plastic surgeons to
evaluate breast implant patients longitudinally using the Butterfly
iQ+ and its innovative Ultrasound-on-Chip™ technology.
Breast implant surgery is one of the most frequently performed
cosmetic or reconstructive surgical procedures in the United
States. In recent years, ultrasound has emerged as a powerful tool
for monitoring the long-term health of patients with breast
implants. Through this unique partnership, Butterfly Network and
Sientra are providing easy access for plastic surgeons to provide
real-time, in-office diagnostic screening of their patients.
“At Sientra, patient safety and product quality remain our
highest priorities, which is why we entrust our breast implants to
only the most qualified surgeons in the industry,” said Ron
Menezes, President and Chief Executive Officer of Sientra. “We are
excited to partner with Butterfly Network to build on the long-term
clinical and real-world data supporting the safety of our breast
implants and equip surgeons with innovative technology to provide
superior care to their patients.”
“Our partnership with Sientra highlights the ability for
Butterfly iQ+ to deliver actionable and diagnostic insights as an
advanced assessment tool, allowing for more informed clinical
decision making, improving the patient experience,” said Dr. Todd
Fruchterman, Butterfly Network’s President and Chief Executive
Officer. “Sientra’s commitment to patient safety mirrors our own
and complements our innovative approach to transforming care
through technology. Butterfly Network’s mission is to democratize
healthcare by making medical imaging accessible to everyone
worldwide. With Sientra, we look forward to raising the bar in
implant safety and reimagining the quality of care that patients
receive.”
As part of Sientra’s commitment to safety and innovation,
Butterfly iQ+ will be integrated into Sientra’s medical education
platform and peer-to-peer network.
To purchase the Butterfly iQ+ ultrasound system,
visit: www.sientra.com/butterfly. Butterfly iQ+ is a
prescription device intended for trained and qualified healthcare
professionals only.
About SientraHeadquartered in Santa Barbara,
California, Sientra is a medical aesthetics company uniquely
focused on plastic surgeons. The Company mission is to offer
proprietary innovations and unparalleled partnerships that
radically advance how plastic surgeons think, work and care for
their patients. Sientra has developed a broad portfolio of products
with technologically differentiated characteristics, supported by
independent laboratory testing and strong clinical trial outcomes.
The Company’s Breast Products Segment includes its Sientra round
and shaped breast implants, the first fifth generation breast
implants approved by the FDA for sale in the United States, its
ground-breaking Allox2® breast tissue expander with patented
dual-port and integral drain technology, and BIOCORNEUM®, the #1
performing, preferred and recommended scar gel of plastic
surgeons(*).
Sientra uses its investor relations website to publish
important information about the Company, including information that
may be deemed material to investors. Financial and other
information about Sientra is routinely posted and is
accessible on the Company’s investor relations website
at www.sientra.com.
*Data on file
About Butterfly NetworkFounded by Dr. Jonathan
Rothberg in 2011, and recently listed on the New York Stock
Exchange through a business combination with Longview Acquisition
Corp., Butterfly created the world's first handheld, single probe
whole-body ultrasound system using semiconductor technology, the
Butterfly iQ+. Butterfly’s mission is to democratize medical
imaging and contribute to the aspiration of global health equity,
making high-quality ultrasound affordable, easy-to-use, globally
accessible, and intelligently connected, including for the 4.7
billion people around the world lacking access to ultrasound.
Through its proprietary Ultrasound-on-Chip™ technology, Butterfly
is paving the way for earlier detection and remote management of
health conditions around the world. The Butterfly iQ+ can be
purchased online today by healthcare practitioners in the United
States, Australia, Austria, Belgium, Canada, Denmark, Finland,
France, Germany, Ireland, Italy, the Netherlands, New Zealand,
Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the
United Kingdom.
Butterfly iQ+ is a prescription device intended for trained and
qualified healthcare professionals only.
Sientra, Inc. Forward Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
based on management’s current assumptions and expectations of
future events and trends, which affect or may affect Sientra’s
business, strategy, operations or financial performance, and actual
results may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements are made only as of the date of this
release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’
‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’
‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of
those terms, and similar expressions that convey uncertainty of
future events or outcomes are intended to identify estimates,
projections and other forward-looking statements. Forward-looking
statements may include information concerning the future popularity
of breast augmentation and reconstruction procedures, the adoption
of ultrasound as a diagnostic tool for breast implant patients, the
ability of plastic surgeons to provide real-time, in-office
diagnostic screening of breast implant patients. Such statements
are subject to risks and uncertainties, including the continuing
popularity of augmentation and cosmetic procedures, the Sientra’s
ability to recapture delayed procedures resulting from the COVID-19
pandemic, the positive reaction from plastic surgeons and their
patients to Sientra’s Breast Products, the positive reaction from
plastic surgeons and patients to Sientra’s marketing, sales and
educational programs, and the ability to execute on the Company’s
commercial, product development and manufacturing initiatives.
Additional factors that could cause actual results to differ
materially from those contemplated in this press release can be
found in the Risk Factors section of Sientra’s public filings with
the Securities and Exchange Commission. All statements other than
statements of historical fact are forward-looking statements. The
words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’
‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’
‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms,
and similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. You are cautioned not to place undue
reliance on these forward-looking statements, and such estimates,
projections and other forward-looking statements speak only as of
the date they were made, and, except to the extent required by law,
the Company undertakes no obligation to update or review any
estimate, projection or forward-looking statement. Actual results
may differ from those set forth in this press release due to the
risks and uncertainties inherent in the Company’s business.
Butterfly Network, Inc. Forward Looking
StatementsThis press release includes “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the United States Private Securities Litigation Reform Act of 1995.
Butterfly’s actual results may differ from its expectations,
estimates, and projections and, consequently, you should not rely
on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,”
“forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believes,” “predicts,” “potential,” “continue,” and
similar expressions (or the negative versions of such words or
expressions) are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, Butterfly’s goals and expectations with respect to its
strategic partnership with Sientra, including its impact on implant
safety and quality of care, and Butterfly’s development and
commercialization efforts and business plans under the caption
“About Butterfly Network.” These forward-looking statements involve
significant risks and uncertainties that could cause the actual
results to differ materially from those discussed in the
forward-looking statements. Most of these factors are outside of
Butterfly’s control and are difficult to predict. Factors that may
cause such differences include, but are not limited to: the impact
of COVID-19 on Butterfly’s business; the ability to recognize the
anticipated benefits of its business combination with Longview
Acquisition Corp.; Butterfly’s ability to grow and manage growth
profitably; the success, cost and timing of Butterfly’s product and
service development activities; the potential attributes and
benefits of Butterfly’s products and services; Butterfly’s ability
to obtain and maintain regulatory approval for its products, and
any related restrictions and limitations of any approved product;
Butterfly’s ability to identify, in-license or acquire additional
technology; Butterfly’s ability to maintain its existing license,
manufacture, supply and distribution agreements; Butterfly’s
ability to compete with other companies currently marketing or
engaged in the development of products and services that Butterfly
is currently marketing or developing; changes in applicable laws or
regulations; the size and growth potential of the markets for
Butterfly’s products and services, and its ability to serve those
markets, either alone or in partnership with others; the pricing of
Butterfly’s products and services and reimbursement for medical
procedures conducted using its products and services; Butterfly’s
estimates regarding expenses, revenue, capital requirements and
needs for additional financing; Butterfly’s financial performance;
Butterfly’s ability to raise financing in the future; and other
risks and uncertainties indicated from time to time in Butterfly’s
filings with the Securities and Exchange Commission. Butterfly
cautions that the foregoing list of factors is not exclusive.
Butterfly cautions you not to place undue reliance upon any
forward-looking statements, which speak only as of the date of this
press release. Butterfly does not undertake or accept any
obligation or undertake to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Butterfly’s expectations or any change in events, conditions or
circumstances on which any such statement is based.
Sientra Contacts:MediaLisa
RosasMarketing@sientra.com
InvestorsLeigh SalvoLeigh@gilmartinir.com
Butterfly Network
Contacts:MediaMedia@butterflynetinc.com
InvestorsAgnes
Lee650.677.9138alee@butterflynetinc.com
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Apr 2024 to May 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From May 2023 to May 2024